GlyH-101 has CFTR-independent effects. In HEK293T cells without detectable CFTR, 10 μM GlyH-101 for 10 min reduced store-operated calcium entry. In a separate patch-clamp design, 50 μM inhibited Orai1/STIM1-mediated inward currents, whereas 0.5 and 5 μM did not significantly inhibit them. These findings limit attribution of cellular responses to CFTR alone; the calcium-entry and current assays used different exposure conditions. [3]
Voltage-dependent inhibition of human CFTR current
Cell-based study · Fisher rat thyroid cells stably expressing wild-type human CFTR [1]
Extracellular GlyH-101 inhibited forskolin-activated CFTR currents more potently at positive voltages. The current-voltage relationship recovered after washout. Apparent potency depends on assay voltage.
Literature-Reported Treatment Conditions
- Treatment concentration
- Dose-response: 0–50 μM; representative 10 and 30 μM conditions
- Method
- Extracellular perfusion during whole-cell patch clamp at room temperature
- Co-treatment
- CFTR activated with 5 μM forskolin
- Reported limits
- Exposure duration and final DMSO concentration for this patch-clamp experiment are not specified in the selected methods/caption.
Methods and source locations
Compound reported in the paper: GlyH-101; Compound label in the paper: GlyH-101
Compound-level research evidence; no Adooq lot, salt-equivalence or stereoisomer-specific validation.
Figure 5A-C; Patch-clamp Analysis of CFTR Inhibition Mechanism; patch-clamp methods
Inhibition of CFTR chloride current at +60, +20, −20 and −60 mV: Hill fit to whole-cell current inhibition — Figure 5C caption and Results
Current-voltage relationship following removal of 10 μM GlyH-101: Whole-cell recording; no-inhibitor, GlyH-101 and washout conditions — Figure 5B image/caption and Results
CFTR F342A mutation increases apparent GlyH-101 potency
Cell-based study · Xenopus laevis oocytes expressing wild-type or F342A CFTR together with human β2-adrenergic receptor [2]
The F342A mutant showed much lower voltage-adjusted EC50 than wild-type CFTR. This is functional evidence consistent with a pore binding model; it is not a direct structural determination of binding.
Literature-Reported Treatment Conditions
- Treatment concentration
- Whole-cell methods specify 1 nM–100 μM across blockade measurements
- Method
- Extracellular application during two-electrode voltage clamp
- Co-treatment
- 10 μM isoproterenol plus 1 mM IBMX stimulation
- Reported limits
- GlyH-101 supplier, final vehicle concentration and exposure time for the EC50 series are not specified in the selected methods.
Methods and source locations
Compound reported in the paper: GlyH-101; Compound label in the paper: GlyH-101
Compound-level research evidence; no Adooq lot, salt-equivalence or stereoisomer-specific validation.
Figure 1B-C and caption; Figure 8A and caption; Table 1 wild-type row; F342A Results; Whole-Cell Recordings and Reagents
GlyH-101 inhibition of wild-type and F342A CFTR at 0 mV: Dose-response fitting at each voltage followed by modified Woodhull analysis — Figure 1C caption; Table 1 wild-type row; Figure 8A caption and Results
CFTR-independent inhibition of store-operated calcium entry
Cell-based study · HEK293T cells with no detectable CFTR in the reported qPCR and immunoblot controls [3]
GlyH-101 reduced SOCE peak amplitude and rate in cells without detectable CFTR. DMSO controls and CFTR-expressing Calu-3 cells for expression controls support a CFTR-independent effect.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μM GlyH-101
- Exposure duration
- 10 min pretreatment before the second calcium addback
- Method
- Fura-2 calcium fluorimetry with repeated calcium addback
- Vehicle
- DMSO; methods keep DMSO ≤0.2%
- Co-treatment
- 200 nM thapsigargin store depletion and 1 mM calcium addback
- Reported limits
- Exact DMSO concentration for this condition and whether the reported ± denotes SD or SEM are not specified.
Methods and source locations
Compound reported in the paper: GlyH-101; Compound label in the paper: GlyH-101
Compound-level research evidence; no Adooq lot, salt-equivalence or stereoisomer-specific validation.
Figure 2A-F; SOCE Results; Intracellular Ca2+ measurements; Chemicals; Statistics
Inhibition of SOCE peak amplitude: Second SOCE response compared with first; one-way ANOVA with Holm-Sidak comparisons; ± type unspecified — Results: CFTRinh-172 and GlyH-101 inhibit SOCE in epithelial cells that do not express CFTR; Figure 2F caption
Inhibition of initial SOCE rise rate: Linear regression of initial calcium rise; second vs first response; ± type unspecified — Same SOCE Results paragraph and Figure 2F caption
Concentration-dependent effects on Orai1/STIM1 currents
Cell-based study · HEK293T cells overexpressing Orai1/STIM1, compared with mock-transfected cells [3]
GlyH-101 significantly inhibited CPA-activated inward currents at 50 μM in Orai1/STIM1-expressing cells; lower concentrations did not significantly affect currents. Mock-transfected currents were unaffected. Docking did not reliably identify an Orai1 binding site.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.5, 5 and 50 μM GlyH-101
- Exposure duration
- 3 min at each concentration
- Method
- Fast whole-cell patch-clamp recordings
- Vehicle
- DMSO; methods keep DMSO ≤0.2%
- Co-treatment
- 10 μM cyclopiazonic acid (CPA) maintained during inhibitor application
- Reported limits
- No IC50 or reliable molecular binding-site assignment was established.
Methods and source locations
Compound reported in the paper: GlyH-101; Compound label in the paper: GlyH-101
Compound-level research evidence; no Adooq lot, salt-equivalence or stereoisomer-specific validation.
Figure 3D-F; Orai1/STIM1 Results including docking limitation; Transfection; Whole cell patch clamp; Chemicals
CPA-activated inward currents, normalized at −100 mV: Whole-cell current measurement with mock-transfected controls; unpaired t-test as specified in caption — Figure 3D-F image/caption; Orai1/STIM1 Results